Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), and G-protein coupled estrogen receptor 1 (GPER1) (ERα, ERβ, GPER1 (or GPER))

The estrogen receptor pathway comprises nuclear receptors (ERα, ERβ) and a membrane G-protein coupled receptor (GPER1), which are activated by estrogens such as estradiol. Upon activation, ERα and ERβ act as ligand-dependent transcription factors regulating gene expression via classical (ERE-dependent) and non-classical (ERE-independent) mechanisms. GPER1 mediates non-genomic signaling via G proteins. These pathways tightly regulate cell growth, differentiation, survival, apoptosis, and metabolic functions across multiple tissues. Dysregulation can cause diverse diseases including hormone-dependent cancers, metabolic syndrome, cardiovascular disease, and reproductive and neurodegenerative disorders. Drugs targeting these pathways may act as antagonists, agonists, or degraders, altering gene transcription or intracellular signal transduction for therapeutic effect[1][2][3][4][5].

Other names

Estrogen receptor (ER)Estrogen receptors alpha and betaG-protein coupled estrogen receptorGPERERα, ERβ

Antagonism (blocking receptor activation by endogenous estrogens, e.g. Tamoxifen); Degradation (e.g. Fulvestrant induces receptor degradation); Agonism (mimicking estrogen activation, e.g. Estradiol, G-1); Allosteric modulation; Modulation of transcriptional activity and coactivator recruitment